Nutriband Inc. is a pharmaceutical development company focused on creating abuse-deterrent transdermal drug delivery systems using its proprietary AVERSA™ technology, which incorporates taste and sensory aversive agents into patches containing opioids, stimulants, and other drugs susceptible to misuse. The company currently generates revenue through two contract-services subsidiaries—Pocono Pharmaceuticals (contract manufacturing for health and pharmaceutical products) and 4P Therapeutics (contract research and development)—while pursuing development of its lead AVERSA™ Fentanyl product and an expanding pipeline including abuse-deterrent buprenorphine and methylphenidate formulations as well as transdermal delivery systems for traditionally injectable off-patent medications. Future revenues are expected from FDA approval and commercial sales of its pharmaceutical products, priced competitively with existing non-abuse-deterrent alternatives, while near-term revenue remains dependent on its established contract services operations.